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Clinical Outcomes (continued)
• Institutional Review Board (IRB)-approved 
• Electronic health record (EHR)-based retrospective chart 
review of patients admitted to any of the eight 
emergency departments in a large multicenter hospital 
organization
• Data was narrowed down by the inclusion criteria and 
the “SlicerDicer” tool within EPIC was utilized to extract 
the included study population.
• Study period: October 1, 2019 – October 1, 2020
• Inclusion criteria: patients admitted for either ACEi 
induced angioedema or HAE and treated with either TXA 
or Berinert during their emergency department visit. 
• Exclusion criteria: patients <18 years of age, patients 
with suspected or confirmed pregnancy, those with an 
allergy or intolerance to TXA or Berinert, patients who 
were treated with any other drug besides TXA or 
Berinert, those with personal or religious objections to 
receiving blood products and finally patients with stage 
one angioedema.
• Primary outcomes: admission to the ICU, intubation rate 
and length of stay (LOS).
Patient Population
• Average patient was a 60-year-old Caucasian male 
weighing 101 kg with a history of a home use of an ACEi 
with a chief complaint of tongue swelling. 
• The mean age was 56 years (range 39-67 years) in the TXA 
group and 76 years (range 65-88 years) in the Berinert 
group.
• 94.4% of patients in total reported taking a home ACEi 
(83.3%) or ARB (11.1%) prior to admission.
Clinical Outcomes
• In the TXA cohort, 50% (n=7) patients were admitted to 
the hospital with 35.7% of patients in this cohort (n=5) 
admitted to the ICU. The remaining patients, 14.3% (n=2) 
were admitted to the medicine floor. 
• The average LOS for patients treated with TXA was 1 day 
(range of 1 day) and there was no incidence of bleeding in 
this group. 
• Patients in the Berinert cohort had a 25% incidence of 
intubation (n=1). 50% (n=2) of patients were admitted to 
the hospital with both patients being admitted to the ICU. 
• The average LOS for patients treated with Berinert was 2.5 
days (range of 1-4 days) and 25% (n=1) patient was 
reported to have copious amounts of blood from his 
mouth. There was no charting to explain the etiology of 
the bleed in this particular patient. 
• For both cohorts, there was no incidence of mortality, 
anaphylaxis or thrombosis. 
Financial Implications
• The average cost of 1 gram dose of TXA is $6 compared to 
$13,617 for Berinert. If one were to estimate an arbitrary 
15 incidences of bradykinin mediated angioedema cases in 
a year, the average cost of TXA would be $90 compared to 
an estimated annual cost of $204,255 of Berinert.
• This is a 2,270-fold price difference. 
Study Limitations
• Retrospective chart review 
• Disproportionate sizes of cohorts
• The study did not reach the sample size required for 
adequate power to assess the primary outcomes of ICU 
admissions, intubation rate, and LOS. 
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• Bradykinin mediated angioedema is an overarching term 
that includes idiopathic angioedema, angiotensin 
converting enzyme inhibitor (ACEi) induced angioedema 
and hereditary angioedema (HAE). 
• This is an emergent condition that must be treated with 
the utmost urgency due to the fatal outcomes associated 
with the rapid constriction of the throat.
• Bradykinin mediated angioedema is treated differently 
from histamine associated angioedema due to its 
resistance to corticosteroids and antihistamines.
• HAE and ACEi induced angioedema are treated similarly 
but there is a lack of unanimity in the first line 
pharmacologic treatment.
• Current treatment options include fresh frozen plasma, 
bradykinin-2 receptor antagonists, plasma-kallikrein 
inhibitors and C1 esterase inhibitors.
• Tranexamic acid (TXA) has been used for moderate cases 
of angioedema but is not well established in the 
emergent setting.
• TXA has a 2270-fold lower cost compared to the 
preferred agent at this large multicenter hospital 
organization, Berinert.
Table 2. Clinical Outcomes of Patients 
Purpose
• The purpose of this study is to examine whether TXA is a 
viable first-line treatment option for bradykinin-
mediated angioedema in the emergency department. 
Methodology
• Determine whether TXA is a viable treatment option for 
bradykinin-mediated angioedema
• Evaluate the cost-effectiveness of TXA in comparison to 
Berinert
• Examine the incidence of use of TXA versus other 
pharmacologic agents used to treat bradykinin-mediated 
angioedema
• Identify the optimal or standard dose of oral TXA for 
patients presenting to the emergency department with 
bradykinin mediated angioedema
Patient Demographics and Clinical Outcomes 
Health & Services
Table 1. Patient Baseline Demographics 
Financial Comparisons
Table 3. Costs of agents used to treat bradykinin-mediated angioedema
*In accordance with primary literature, US retail pricing obtained from www.drugs.com on April 6, 2021
Figure 1. Admissions by Department Figure 2. Average LOS (days)
• This small study showed the potential for utilization of 
intravenous TXA as a first line agent for bradykinin-mediated 
angioedema. 
• A larger study population would need to be assessed to 
confirm the benefits of using intravenous tranexamic acid 
over a C-1 esterase inhibitor such as Berinert as a first line 
agent for bradykinin-mediated angioedema. 
• By utilizing a more cost effective and possibly safer agent 
such as tranexamic acid, providers may not only improve 
outcomes for patients but also reduce costs for a large 
multicenter healthcare system.
Figure 3. Comparison of clinical outcomes 
